The reason? An experimental therapy for the treatment of obesity has failed to meet expectations.
The drug CagriSema achieved a weight loss of 22.7% in a phase 3 trial with obesity patients. Novo Nordisk had originally expected a reduction of up to 25%.
I seized the opportunity and finally bought in. I will now continue to buy more. 📈
